Zydus’ Nesher Pharma gets USFDA nod to market influenza drug

By: |
New Delhi | Published: September 16, 2017 7:04:03 PM

Drug firm Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir used for treatment and prevention of influenza.

Zydus' Nesher Pharma, Zydus, Nesher Pharma, USFDA, market influenza drug, USFDA nod to market influenza drug, Zydus Cadila, market Oseltamivir, prevention of influenza, Nesher PharmaceuticalsDrug firm Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir used for treatment and prevention of influenza. (Image: Reuters)

Drug firm Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir used for treatment and prevention of influenza. “Zydus’ Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6 mg/ml…”, Zydus Cadila said in a statement. The product is used in the treatment and prevention of influenza, it added.

The drug will be produced at Nesher Pharmaceuticals’ manufacturing facility located at St Louis, US, Zydus Cadila said. The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company’s filing process.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Planters seek moratorium on rubber imports
2IBC ordinance: No fresh default case for a year from Mar 25
3SBI Q4 net shoots up 327% year-on-year on one-time gain